Clinical Trial Update: A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes. [Phase 2]

View source ↗

Summary

A Phase 2 long-term safety and tolerability study of GK Activator (2) in adults with Type 2 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• GK Activator (2)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Diabetes Mellitus Type 2 | Phase 2 | Status: COMPLETED